Clinical Data Engineer

Cytovale appoints Eric Khairy as Chief Marketing Officer. PR Newswire Today at 6:15am PDT Veteran MedTech commercial leader brings over two decades of operating experience to drive program-building enabled by company's rapid sepsis test SAN FRANCISCO, April 7, 2026 /PRNewswire/ - Cytovale(R), a commercial-stage medical diagnostics company focused on the early detection of sepsis, today announced the appointment of Eric Khairy as Chief Marketing Officer. In this newly created role, Khairy will lead global marketing strategy and execution as the company accelerates adoption of its IntelliSep(R) rapid sepsis test. "Eric brings deep commercial experience from high-growth top-tier MedTech organizations," said Cytovale CEO Ajay Shah. "He has successfully built and scaled teams that support product adoption and growth, and he understands how to translate clinical innovation into broad patient impact. His expertise strengthens our executive leadership team as we bring IntelliSep to more emergency departments across the nation." Khairy joins Cytovale from Inari Medical where he served as Senior Vice President of Marketing and Commercial Operations, helping to fuel the company's growth from $6 million to $600 million in annual revenue over his seven-year tenure, from startup through a $1 billion IPO and subsequent $4.9 billion acquisition by Stryker. Prior to Inari, Khairy held commercial and strategy leadership roles at Philips, Volcano, Corindus Vascular Robotics, and Minogue Medical. "Sepsis is a leading cause of in-hospital death and the most expensive condition to treat, and every hour of delayed treatment costs lives. We can do better," Khairy said. "Cytovale's IntelliSep delivers an actionable sepsis test result in 8 minutes, not days. This solution has already reached over 65,000 patients, and I'm excited to accelerate its adoption." Khairy holds an MBA from MIT, an M.A.Sc. in biomedical engineering from the University of Montreal, and a B.Eng. in computer engineering from McGill University. About IntelliSep(R) IntelliSep is Cytovale's U.S. Food and Drug Administration-cleared rapid sepsis diagnostic, which leverages artificial intelligence (AI) and advanced microfluidics to provide Emergency Department clinicians with an objective and highly sensitive early detection tool for sepsis. IntelliSep assesses the body's dysregulated immune system response to infection and provides a risk score for sepsis within approximately eight minutes using a standard blood draw. For more information, visit cytovale.com/our-solution/intellisep-sepsis-test/. About Cytovale(R) Cytovale is committed to improving patient care by pioneering early detection technologies that assess immune activation to accelerate the time it takes to get from triage to life-saving therapies. Cytovale developed IntelliSep(R), the U.S. Food and Drug Administration-cleared rapid sepsis diagnostic for use with a standard blood draw in Emergency Departments to determine risk of sepsis. Cytovale is based in San Francisco and venture-backed by Norwest Venture Partners, Sands Capital and Global Health Investment Corporation (GHIC). For more information, visit cytovale.com and follow Cytovale on LinkedIn. SOURCE Cytovale This is a paid placement. For further inquiries, please contact PR Newswire directly.

Cytovale's IntelliSep ® sepsis test highlights a new model for ED triage that's already delivering systemwide clinical and economic valueResults of real-world study with 12,000+ patients published in the journal HealthcareSAN FRANCISCO, June 12, 2025 /PRNewswire/ -- One of the largest real-world studies of a sepsis diagnostic reveals that Cytovale's IntelliSep®, a U.S. Food and Drug Administration (FDA)-cleared rapid host response diagnostic, reduced the relative rate of sepsis mortality by 39%, shortened length of hospital stay and enabled more efficient resource allocation in the emergency department (ED). The study, " Impact of a Sepsis Quality Improvement Initiative on Clinical and Operational Outcomes ," published in the peer-reviewed journal Healthcare, followed more than 12,000 patients over 12 months at Our Lady of the Lake Regional Medical Center (OLOLRMC), a 900-bed in-patient acute care facility and Level 1 trauma center in Baton Rouge, La."This is the kind of data the medical field has been waiting for and the results represent a breakthrough in sepsis care," said Dr. Christopher Thomas, study author who serves as Vice President and Chief Quality Officer at Franciscan Missionaries of Our Lady Health System (FMOLHS) and is a critical care physician at Louisiana State University Health Sciences Center. "With this small operational change, we are able to save more lives, deliver better care faster and optimize use of hospital resources. It's a pivotal step forward in how emergency departments manage sepsis

Seasoned nurse executive and health IT leader to drive expansion of nurse-driven sepsis protocol leveraging IntelliSep® rapid detection solutionSAN FRANCISCO, March 18, 2025 /PRNewswire/ -- Cytovale® , a commercial-stage medical diagnostics company, today announced the appointment of Rhonda Collins, DNP, RN, FAAN, as the company's first chief nursing officer (CNO). A former nurse, seasoned hospital executive and leader in healthcare IT, Collins will oversee Cytovale's clinical consultant team as they engage with hospital executives around the country to implement nurse-driven sepsis protocols with the company's rapid sepsis detection solution, IntelliSep® ."We've seen strong clinical improvements – including a 30% reduction in risk-adjusted mortality – when hospitals use IntelliSep as part of a nurse-driven sepsis protocol in their emergency departments. We're now looking to bring that same protocol to hospitals across the U.S.," said Ajay Shah, Cytovale co-founder and CEO. "Rhonda, with her deep understanding of nursing workflows and implementing new technologies, will be instrumental in helping more hospitals develop effective sepsis protocols that empower the nursing staff and benefit their patients."A registered nurse for over three decades, Dr. Collins was a hospital executive before continuing her evolution to become a leader in healthcare IT. She comes to Cytovale from Kontakt.io, where she served as CNO